GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK

Stock price

GENMAB

Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial

8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

Filing	Date
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis	20 Aug 2020
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.	20 Aug 2020
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma	20 Aug 2020
Genmab A/S has published its Articles of Association	19 Aug 2020
Capital Increase in Genmab as a Result of Employee Warrant Exercise	18 Aug 2020
Genmab Announces Financial Results for the First Half of 2020	12 Aug 2020
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma